Drugs / Bortezomib
Bortezomib
DrugBortezomib is an anti-cancer proteasome inhibitor used primarily in multiple myeloma and mantle cell lymphoma. It is marketed under brand names including Velcade and administered by injection. The drug has been approved in the U.S. since 2003.
- Trials
- 935
- Recruiting
- 67
- Completed
- 516
- With results
- 315
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | Active | Completed | Terminated | Withdrawn | Unknown | Available | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 2 | — | — | 3 | 2 | 1 | 1 | — | — | 9 |
| Phase 1 | 4 | 1 | 6 | 126 | 29 | 5 | 4 | — | — | 175 |
| Phase 1/2 | 8 | 3 | 6 | 54 | 20 | 8 | 12 | — | — | 111 |
| Phase 2 | 28 | 3 | 30 | 245 | 76 | 20 | 38 | — | — | 440 |
| Phase 2/3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | — | — | 8 |
| Phase 3 | 18 | 5 | 28 | 54 | 8 | 2 | 9 | — | — | 124 |
| Phase 4 | 2 | 1 | 1 | 8 | 1 | 3 | 7 | — | — | 23 |
| Not applicable | 1 | — | — | 8 | 2 | — | 5 | — | — | 16 |
| Unknown | 3 | 1 | — | 16 | — | — | 5 | 1 | 3 | 29 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Multiple Myeloma | 4 | 69 | 56 | 188 | 5 | 95 | 9 | 4 | 22 | 452 |
| Neoplasms, Plasma Cell | 1 | 14 | 11 | 32 | — | 10 | — | — | 1 | 69 |
| Recurrence | — | 8 | 16 | 28 | — | 12 | 2 | — | 1 | 67 |
| Lymphoma, Mantle-Cell | — | 19 | 10 | 34 | — | 2 | — | 1 | — | 66 |
| Lymphoma | 1 | 20 | 8 | 32 | 2 | 1 | — | 1 | — | 65 |
| Lymphoma, Non-Hodgkin | — | 15 | 9 | 17 | — | 1 | — | 1 | — | 43 |
| Lymphoma, Follicular | — | 13 | 7 | 20 | — | — | — | 2 | — | 42 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | — | 15 | 8 | 13 | 1 | 1 | 1 | 2 | — | 41 |
| Leukemia, Myeloid, Acute | — | 17 | 8 | 9 | — | 1 | — | 1 | — | 36 |
| Lymphoma, Large B-Cell, Diffuse | — | 14 | 5 | 13 | — | 1 | — | 1 | — | 34 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | National Cancer Institute (NCI) | 91 | 5 |
| 2 | Millennium Pharmaceuticals, Inc. | 30 | 6 |
| 3 | M.D. Anderson Cancer Center | 27 | 0 |
| 4 | Janssen Research & Development, LLC | 25 | 14 |
| 5 | Dana-Farber Cancer Institute | 23 | 1 |
| 6 | University of Arkansas | 20 | 7 |
| 7 | PETHEMA Foundation | 18 | 4 |
| 8 | Mayo Clinic | 15 | 0 |
| 9 | Memorial Sloan Kettering Cancer Center | 14 | 0 |
| 10 | GlaxoSmithKline | 12 | 5 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Bortezomib | 935 |
| 2 | Dexamethasone | 362 |
| 3 | Lenalidomide | 145 |
| 4 | Cyclophosphamide | 130 |
| 5 | Calcium Dobesilate | 102 |
| 6 | Rituximab | 98 |
| 7 | daratumumab | 95 |
| 8 | Melphalan | 68 |
| 9 | Doxorubicin | 64 |
| 10 | Thalidomide | 48 |
Evidence
- Results reported
- 61%315 of 516 completed
- Published
- 16.9%87 of 516 completed
- Primary endpoint met
- 35.9%23 of 64 analyses
- Median months to report
- 17
Documents disclosed
Trial profile
- Median enrollment
- 40
- Median duration
- 57months
- Countries
- 68
- Study sites
- 10851
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 11
- Phase 1
- 23
- Phase 1/2
- 42
- Phase 2
- 36
- Phase 2/3
- 35
- Phase 3
- 402
- Phase 4
- 40
- Not applicable
- 22
- Unknown
- 100
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Boston | United States | 131 |
| 2 | New York | United States | 127 |
| 3 | Houston | United States | 95 |
| 4 | Atlanta | United States | 87 |
| 5 | Rochester | United States | 81 |
| 6 | Madrid | Spain | 74 |
| 7 | Chicago | United States | 73 |
| 8 | Barcelona | Spain | 69 |
| 9 | Salamanca | Spain | 68 |
| 10 | Seattle | United States | 65 |
Terminations
- Terminated
- 139
- Withdrawn
- 40
- Stopped for recruitment
- 7.1%66 of 935 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT07428369 Withdrawn | Withdrawn | Sponsor Decision | 2038-05-21 |
| NCT03617484 Withdrawn | Withdrawn | Enrollment and/or interactions/interventions temporarily paused due to COVID-19 and expected to resume in the future. This is not a suspension of IRB approval. | 2030-07-31 |
| NCT06015750 Withdrawn | Withdrawn | Sponsor decision following FDA release from the PMR. | 2030-03-13 |
| NCT06348147 Withdrawn | Withdrawn | budget | 2029-05-31 |
| NCT05408026 Withdrawn | Withdrawn | Study withdrawn, trial therapy deemed no longer novel and there was a lack of site interest. | 2026-02-28 |
| NCT05895201 Withdrawn | Withdrawn | PI has left IU with no plan to initiate study at IU | 2025-12-31 |
| NCT04570631 Terminated | Terminated | Strategic considerations | 2025-05-05 |
| NCT04285268 Withdrawn | Withdrawn | This study was never submitted to the IRB for review and approval. No research subjects were enrolled. . | 2024-09-30 |
| NCT05556616 Terminated | Terminated | Due to strategic reasons (no safety concerns). | 2024-06-04 |
| NCT04892446 Terminated | Terminated | This study was terminated early due to the Sponsor's decision to discontinue development of the investigational drug and close the program. | 2024-04-25 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: